Sadeghi, S., Callis, S., Lara, P. N., Berg, S. A., Brown, J. R., Ayanambakkam, A., Cole, S., Kessler, E. R., Vaena, D. A., Angstreich, G. R., Gourdin, T. S., Mar, N., Bangs, R., Nakagawa, D., Daneshmand, S., Thompson, I. M., Flaig, T. W., Petrylak, D. P., Lerner, S. P. (2026). A phase III randomized trial of eribulin (E) with gemcitabine vs standard of care (SOC) for patients (pts) with metastatic urothelial carcinoma (mUC) refractory to or ineligible for PD/PDL1 antibody (Ab): SWOG S1937—Updated design.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.7_suppl.tps894